

AMENDMENTS TO THE SPECIFICATION

Replace the paragraph at page 77, lines 1-14 (i.e., Table 4), with:

Table 4. MUC-1 peptide analogues

Amino acid sequence	<u>SEQ ID NO:</u>	Initial designation	T2 binding*
ATWGQDVTSV	<u>1</u>	P-92 (native)	510
<i>A</i> WGQDVTSV	<u>14</u>	I-93	823
<i>AL</i> WGQDVTSV	<u>19</u>	L-93	821
<i>AL</i> WGQDVTS <i>L</i>	<u>15</u>	L-93/L-101	736
<i>AM</i> WGQDVTSV	<u>16</u>	M-93	723
<i>AM</i> WGQDVTS <i>L</i>	<u>17</u>	M-93/L-101	325
<i>A</i> WGQDVTS <i>L</i>	<u>18</u>	I-93/L-101	280

Amino acid sequences of the parental P-92 peptide (amino acid positions 92-101 of MUC-1) and analogue peptides. Amino acids are shown by the single-letter code. Substitution amino acids are indicated in bold and italic.

*Results are expressed in relative fluorescence values. HLA-A3 peptide (T2 binding=200) was used as a negative control and CAP1-6D (T2 binding=875) was used as a positive control.